More than 10 years ago, we developed an efficient protocol for serum-free retroviral transduction of human hematopoietic stem cells derived from mobilized peripheral blood. After upscaling of the methodology, serum-free retroviral gibbon-ape leukemia virus (GALV) pseudotype PG13/LN vector supernatant produced under strict good manufacturing practice (GMP) conditions was used in the first clinical gene-marking trial in Germany. In this study, we analyzed the titer and transduction efficiency of this serum-free clinical-grade retroviral supernatant 10 years after production to evaluate the long-term stability. Long-term storage and transport on dry ice resulted in modestly decreased titers and levels of transduction efficiency in CD34 + cells ranging from 38.4 to 49.1%. We conclude that the stability of retroviral vectors in serum-free medium allows extended storage and distribution of approved clinical-grade retroviral vector stocks to distant sites in multicenter clinical trials.
INTRODUCTION
Gene therapy of the hematopoietic system using gammaretro-or lentiviral vectors for the transfer of therapeutic transgenes has proven efficient in the treatment of inherited diseases of the blood-forming system, including immunodeficiencies and storage disorders. In 1997, we established a protocol for the efficient transduction of human hematopoietic stem cell transplants derived from mobilized peripheral blood under serum-free conditions 1 that we applied in the first German clinical gene-marking study in patients with chronic-phase CML. 2 Besides ensuring improved biosafety, bovine or horse serum was avoided to improve viral stability, help the expansion of hematopoietic progenitors 3 and obtain enhanced retroviral transduction while maintaining the engraftment capability of transplanted repopulating cells. [4] [5] [6] [7] [8] The stability of retroviral vectors during production and transduction depends on several factors, including temperature, pH, medium supplements and producer cell metabolism. [9] [10] [11] In addition, conditions during storage, such as fluctuations in temperature, largely affect the half-life of infectious vector particles. 12, 13 Under appropriate storing, serum-containing retroviral supernatants retain the ability to infect target cells for several years. 14 However, the stability of clinical-grade retroviral vector media without serum in long-term storage for 10 years and during transport has not been studied. To address this question, we analyzed the titers and transduction efficiencies of undisturbed as well as transported serum-free retroviral PG13/LN 15 supernatants immediately and 10 years after production ( Figure 1a) .
RESULTS AND DISCUSSION
The serum-free retroviral vector supernatant was stored for 10 years in cylindrical metal boxes containing multiple polypropylene flasks with 100 ml of vector stocks in controlled conditions at À80 1C. For transport, individual metal boxes were embedded in dry ice in large plastic containers and delivered within 24 h. Upon arrival, the complete metal boxes were immediately transferred to À80 1C. Titers of untouched aliquots of vector-containing media and aliquots transferred on dry ice 10 years after production were determined on HeLa cells using the same protocol as in 1997. Compared with the original level of frozen batches immediately tested after production (1.7Â 10 5 ±8.1Â10 4 TU ml À1 ), 1 titers decreased only slightly during longterm storage, and the difference in titers did not reach statistical significance (1.2Â10 5 ± 1.9Â10 4 TU ml À1 ; À1.55-fold; P¼0.3). Transport on dry ice after long-term storage further decreased the titer by a total of 2.30-fold (7.4Â10 4 ±2.9Â10 4 TU ml À1 ; Po0.01) compared with the original titers ( Figure 1b ). Infectivity kinetics for MLV and HIV vectors after frequent thaw and freeze cycles have been shown to lead to vector inactivation more rapidly within the first five circles. 16 Even though no thaw indicators were triggered during transport, and temperatures over dry ice are o-75 1C, we cannot exclude that temperature fluctuations and other ambience changes during transport did affect titers to some degree. As an example, decreased pH caused by CO 2 released from dry ice during the transport of viral stocks has been described to reduce adenoviral titers. 17 Therefore, we examined the pH and osmolality of the long-term stored and transported virus-containing medium. Both pH (7.36 ± 0.02) and osmolality (0.313 ± 0.003) were unchanged as compared with the initial measurements in 1997 (pH 7.39 and osmolality 0.315 osmol kg À1 ).
We then determined whether storage and transport had affected the ability of the vector-containing medium to transduce human CD34 + cells from mobilized peripheral blood. Defective vector particles or shedded envelope proteins could interfere with intact particles and decrease the transduction efficiency on these target cells. The transduction protocols used in this study and in 1997 were identical. 1 After 7 days of transduction culture, the number of total cells increased 1.89±0.73-fold compared with a 3.35±1.16-fold expansion during transduction in 1997. Long-term storage only slightly reduced the ability of the supernatant to support the proliferation of CD34 + peripheral blood stem cells, and this difference did not reach statistical significance (0.56-fold; P40.05). Absolute numbers of CD34 + cells after transduction (day 7) were similar to those from control cultures in fresh medium (CellGro SCGM medium; CellGenix, Freiburg, Germany; supplemented with 1% glutamine, 1% penicillin/streptomycin) without vector (3.19Â10 4 ± 1.32Â10 4 transduced CD34 + cells compared with 2.79Â10 4 ± 1.28Â10 4 CD34 + cells in the untransduced control; P¼0.87; Figure 1c ), indicating that long-term storage of the vector-containing medium did not affect its ability to support human hematopoietic cells in vitro.
Similar to that observed a decade ago, we determined gene transfer efficiency into human CD34 + colony-forming cells (CFCs) by both functional G418 resistance and PCR amplification of the neomycin (neo) reporter sequence from individual colonies. In all, 38.4±2.9% of the CFCs were resistant to G418, and vector was detected in 43 out of 73 colonies. In 1997, gene transfer efficiency into CFCs was only 11.5±5.8% after transduction under clinical large-scale GMP requirements and 49±1.3% under pre-clinical conditions as measured by G418 resistance; vector sequences were detectable in 7 out of 20 colonies (Figures 1d and e) . 1 Even 10 years after production, the To quantify G418 resistance, 1 mg ml À1 G418 (twice the pretested lethal dose) was added to half of the assays. Colonies were counted after 14 days, collected and washed twice with Hank's balanced salt solution supplemented with 2% FBS. In all, 38.4±2.9% of the CFC (2008trans) were resistant to G418, whereas in 1997 gene transfer into colony-forming cells was 49 ± 1.3% in samples transduced under identical lab-scale conditions (1997pre-clin) and 11.5 ± 5.9% under clinical large-scale GMP conditions (1997clin). (e) Gene transfer into CFCs was analyzed by nested PCR amplification of the neomycin reporter sequence of the g-retroviral vector. Genomic DNA was isolated by lysing cells from colonies of transduced and untransduced CD34 + cells on ice for 10 min with 3 ml 400 mM KOH, 10 mM EDTA and 100 mM DTT, followed by neutralization with 3 ml 400 mM HCl and 600 mM Tris-HCl (pH 7.5). PCR amplification of neo and Myoglobin (myo) sequences was performed as described, 1 using the following oligonucleotides: myo-fwd (5¢-TGTGCCCCAGGTTTCTCATTTG-3¢) and myo-rev (5¢-CTCCCAGTGGCACAGCAGTTAGG-3¢), sense primer neo350 (5¢-AAGAGACAGGATGAGGATCG-3¢), antisense primer neo1150 (5¢-CAGAAGAACTCGTCAAGA-3¢). Nested PCR of the neo-amplified products was performed using the sense primer neo450 (5¢-ACAAACAGACAATCGGCTGCT-3¢) and the antisense primer neo1027 (5¢-GCCAACGCTATGTCCTGATA-3¢), resulting in a 598-bp product. In total, 43 of 73 colonies (2008trans) were detected to be vector positive compared with 35% in 1997. Representative examples are shown. Data are presented as mean ± s.d. Statistical significance was assessed using Student's t-test for P-values o0.05. CFU-C, colony-forming unit (in culture).
Long-term stability of c-retroviral vectors F Herbst et al serum-free retroviral supernatant was still functional and capable of efficiently transducing human primary hematopoietic progenitor cells. In summary, these data demonstrate that clinical-grade serum-free retroviral vector supernatant remains stable over a long period of time under appropriate storage conditions. In addition, transport of vector-containing medium on dry ice is feasible, with only a moderate reduction in titers that does not affect the transduction efficiency in primary human hematopoietic cells. We conclude that serum-free clinical-grade vector stocks can be safely distributed to distant sites in multicenter clinical studies.
